Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496884 | 0.91 | MAPT (0.56) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL496631 | 0.86 | KDR (0.46) | TP53GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2028746 | 0.85 | MAPT (0.62) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL496572 | 0.85 | MAPT (0.52) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL496586 | 0.84 | MAPT (0.60) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL2027232 | 0.83 | MAPT (0.67) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL2825575 | 0.82 | MAPT (0.57) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL2024771 | 0.82 | MAPT (0.69) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL2052410 | 0.82 | MAPT (0.57) | MAPTTP53NPC1LMNARAB9A | |
| SCHEMBL2030529 | 0.82 | MAPT (0.60) | MAPTTP53NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | claimed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | claimed |
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | MAPT 3537/4885TP53 4666/4885NPC1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.